BillionToOne Stock

HealthTech

BillionToOne has developed a molecular counter platform designed to enhance the precision of cell-free DNA testing. Their pan-cancer oncology test, which is tumor-naive, accurately measures tumor load from a blood sample, aiding in monitoring responses to therapy. Additionally, BillionToOne's prenatal testing procedure utilizes quantitative biology and statistical learning approaches to maximize the signal-to-noise ratio and detect single-gene disorders. This enables expectant mothers to identify disorders such as sickle-cell disease, beta-thalassemia, spinal muscular atrophy, and cystic fibrosis through a straightforward blood test.